Open

Phase 1 Study for People with Antigen-Positive Locally Advanced or Metastatic Solid Tumors

The study involves research of three study drugs, given alone or in combination. The combination of the study drugs is referred to as T-Plex. The purpose of the study is to learn if the study drugs are well tolerated and effective in treating your type of cancer.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)
Visits can be combined with regular clinical appointments

Location

United States (Nationwide)

What will be asked of you

We will first do some tests to make sure you are able to take part. You will then have Lymphodepletion Chemotherapy about a week before your first dose of study treatment. Depending on the dose level you are assigned, you may receive 1 or 2 doses of treatment. If you are assigned to 2 doses, you will receive the second does 28 days after the first.

Incentives

In-person visits:
Variable - based on disease and side effects

Phone or online visits:
Variable - based on worsened disease

Total length of participation:
Up to 15 years - this includes treatment, short-term follow up, and long term follow-up.

Looking for Specific Volunteers

Able to participate:

You have a diagnosis of an unresectable or metastatic solid tumor and your cancer has not responded to treatment
Presence of at least 1 site of disease that can be measured before starting treatment
You are able to perform daily tasks

Not eligible if:

You have had a heart attack, other major cardiac issues, or a stroke within 12 the past 12 months
Use of corticosteroids at doses of 10 mg or more of prednisone (or its equivalent) within 7 days of enrollment
Involvement of disease in the brain or spinal column that has not been treated and/or remains symptomatic
Active, uncontrolled infection (fungal, bacterial, viral or other) requiring treatment

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Immunotherapy Team
UNCImmunotherapy@med.unc.edu

Primary Visit Location

NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Jared Weiss
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Other Cancers)

IRB Number

23-1443

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.